Glenmark inks a deal for Spiriva in Europe

Glenmark is aiming to bolster its burgeoning respiratory presence in Europe by signing an exclusive licensing and marketing agreement with an undisclosed third party for a generic of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) dry-powder inhaler in Western European markets.  

Glenmark is aiming to bolster its burgeoning respiratory presence in Europe by signing an exclusive licensing and marketing agreement with an undisclosed third party for a generic of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) dry-powder inhaler in Western European markets.

No financial details were disclosed of the deal for the generic treatment of chronic obstructive pulmonary disease (COPD). Quoting Iqvia...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Archive

More from Generics Bulletin